Altimmune to Participate in Upcoming Investor Conferences

October 10, 2019 at 7:00 AM EDT

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:

                                       
 H.C. Wainwright 3rd Annual NASH Investor Conference
 Date:
Time:
Speaker:
Location:
Webcast:
Monday, October 21
11:20am ET
M. Scott Harris M.D., Chief Medical Officer
St. Regis Hotel, New York City
https://ir.altimmune.com/investors/events-and-presentations
   
 BIO Investor Forum
 Date:
Time:
Speaker:
Location:
Webcast:
Wednesday, October 23
12:45pm ET/9:45am PT
Vipin K. Garg Ph. D., President and Chief Executive Officer
Westin St. Francis Hotel, San Francisco, CA
https://ir.altimmune.com/investors/events-and-presentations
   
 Jefferies 2019 London Healthcare Conference
 Date:
Attendees:
 
Location:
November 20 and November 21 (one-on-one meetings only)
Vipin K. Garg Ph.D., President and Chief Executive Officer
Will Brown, Chief Financial Officer
Waldorf Hilton, London, UK
 

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company’s diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcellTM), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShieldTM and NasoVAXTM). For more information on Altimmune, please visit www.altimmune.com.

                      
Contacts 
Will BrownAshley R. Robinson
Chief Financial OfficerManaging Director LifeSci Advisors
Phone: 240-654-1450Phone: 617-535-7742
Email: wbrown@altimmune.comEmail: arr@lifesciadvisors.com
 

 

Altimmune Logo.png

Source: Altimmune, Inc.

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe